Axovant Sciences (AXON), vTv Therapeutics (VTVT) Mechanisms Don't Overlap with Sola - Piper
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Baird Sees Minimal Read Through for Axovant (AXON) on Lilly's Sola Failure
November 23, 2016 12:26 PM ESTBaird analyst Brian Skorney came out to defend Axovant Sciences (NYSE: AXON), which was weaker on Lilly's solanezumab failure. The analyst sees no change for AXON and maintained an Outperform rating and price target of $29.
Skorney commented, "The Alzheimer's field was... More
Axovant Sciences (AXON) Sinks 17% on Eli Lilly Sola Failure
November 23, 2016 7:50 AM ESTAxovant Sciences (NYSE: AXON) is down 17% in pre-open trade after Eli Lilly & Co. (NYSE: LLY) announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).
... MoreAxovant Sciences (AXON): Allergan Acquisition of Chase a Positive - Baird
November 23, 2016 6:36 AM ESTBaird analyst, Brian Skorney, reiterated his Outperform rating on shares of Axovant Sciences (NYSE: AXON) after Allergan (NYSE: AGN) announced the acquisition of Chase Pharmaceuticals, a privately held company focusing on development of fixed-dose combinations in... More
